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Summary
 Background: Th2-cytokines, such as interleukins-4 and –13 (IL-4, IL-13), have been identifi ed as alternative stim-
uli of monocytes/macrophages. We have recently profi led the gene-expression pattern of IL-4-teat-
ed human peripheral monocytes and found that 15-lipoxygenase-1 (15-LOX1) and monoamine 
oxidase A (MAO-A) are among the fi ve most strongly upregulated gene products in IL-4-treated 
cells. Transfection of monocytic cells (U937) with 15-LOX1 also induced MAO-A expression. These 
data suggested that 15-LOX1 products might play a role in the IL4-induced signaling cascade lead-
ing to expression of MAO-A in human monocytes.
 Material/Methods: To test this hypothesis we incubated wild-type and 15-LOX1-transfected U937 cells with different 
concentrations of either IL-4 or 15-LOX-products [13S-H(p)ODE, 15S-H(p)ETE] and quantifi ed 
the expression of 15-LOX1, MAO-A, and MAO-B by activity assays and real-time RT-PCR.
 Results: Wild-type U937 cells express neither MAO-A nor MAO-B, but after three days of IL4 treatment, 
MAO-A mRNA was detected. A similar isoform-specifi c expression of MAO-A mRNA was observed 
when U937 cells were transfected with 15-LOX1 or when the cells were incubated with primary 
15-LOX1 products (hydroperoxy fatty acids) or H2O2. In contrast, the corresponding hydroxy fat-
ty acids were ineffective.
 Conclusions: These data indicate that increased intracellular peroxide concentrations (oxidative stress) induce 
MAO-A expression in monocytes/macrophages, which normally do not express the enzyme. Our 
fi ndings also suggest that IL-4-induced upregulation of MAO-A expression in human peripheral 
monocytes may proceed via 15-LOX1-dependent and 15-LOX1-independent pathways. The bio-
logical role of MAO-A expression for monocyte function is discussed.
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BACKGROUND
Cytokines are powerful mediators of infl ammatory and im-
mune reactions [1–3] and sometimes they are classifi ed as 
pro- or anti-infl ammatory messengers [4]. However, this 
classifi cation is quite simplistic and there is convincing ev-
idence indicating that a given cytokine may exhibit pro- 
and/or anti-infl ammatory activities depending on its con-
centration, the nature of the target cell, and even on the 
experimental infl ammation model [5]. Lymphocyte-de-
rived Th2 cytokines, such as interleukins-4 and –13 (IL-4, 
IL-13), regulate gene expression of infl ammatory and/or 
immune competent cells. In human peripheral monocytes 
they appear to induce an anti-infl ammatory response [6]. 
Expression of classic pro-infl ammatory cytokines, such as 
IL-1, IL-6, IL-8, and TNF, is down-regulated by these cy-
tokines and the pattern of CD cell-surface antigens is dra-
matically altered [6]. It has been reported previously that 
15-LOX1 is strongly upregulated during treatment of pe-
ripheral monocytes with IL-4 [7] and recent microarray stud-
ies indicate that 15-LOX1 constitutes the most strongly up-
regulated gene product. [8]. LOXs form a diverse family 
of lipid peroxidizing enzymes capable of oxygenating pol-
yunsaturated fatty acids to the corresponding hydroperox-
ides [9]. They have been implicated in the biosynthesis of 
infl ammatory mediators [10], in cell development [11,12], 
and in the pathogenesis of various diseases [13–15]. The 
mechanism of IL-4/-13-induced upregulation of 15-LOX1 
expression involves functional IL-4/-13 cell surface recep-
tors [16], various protein kinases [17,18], and members of 
the STAT transcription factor family [19,20]. Under rest-
ing conditions the STAT-responsive cis-regulatory elements 
in the 15-LOX1 promoter [21] appear to be blocked by 
nuclear histones so that activated transcription factors are 
prevented from binding. However, IL-4 treatment activates 
nuclear acetyltransferases catalyzing acetylation of nuclear 
histones, and this covalent modifi cation induces conforma-
tional alterations in the nucleosome structure rendering the 
cis-regulatory elements of the 15-LOX1 promoter accessi-
ble for activated trans-acting proteins [21].
15-LOX1 is a pro-oxidative enzyme and its cytokine-depend-
ent upregulation increases the intracellular oxidizing po-
tential [22]. Another pro-oxidative enzyme is monoamine 
oxidase (MAO, EC 1.4.3.4). This enzyme has been charac-
terized as an FAD-containing protein converting biogenic or 
dietary amines to the corresponding aldehydes [23,24]. The 
enzymatic reaction requires molecular dioxygen and pro-
duces stoichiometric amounts of hydrogen peroxide [23]. 
In mammalian cells the aldehyde intermediates are rapidly 
oxidized via aldehyde dehydrogenase to the corresponding 
acid or, alternatively, are reduced to alcohols. The hydrogen 
peroxide formed via MAO-catalyzed oxidative deamination 
increases the cellular oxidizing potential. MAO is located 
in the outer mitochondrial membrane as well as in the cy-
tosol [25], and there are two genetic isoforms, MAO-A and 
MAO-B [23,24]. They are encoded by separate genes, have 
different protein-chemical properties, and exhibit distinct 
substrate and inhibitor specifi cities [26–28]. Recent inves-
tigations into the molecular reasons for the enzymatic dif-
ferences suggested that a single amino acid exchange is re-
sponsible [29,30]. Although MAO-A and MAO-B occur in 
many cells, there are differences in tissue- [31,32] and devel-
opment-specifi c expression patterns [33,34]. For instance, 
MAO-A is expressed at a high-level in placenta [35], but in 
pre-eclamptic patients its expression level is reduced [36].
The two genes encoding MAO-A and MAO-B are localized 
on the X-chromosome [37,38]. They contain 15 exons and 
the exon-intron organization is very similar [39]. The 5’-
fl anking regions of the two genes share a high degree of se-
quence similarity, but there is a distinct pattern of cis-regula-
tory elements [40]. The basic promoter of the MAO-A gene 
contains four SP1 binding sites and reporter gene assays in-
dicated that three of them are functional [41]. More recent-
ly it was reported that MAO-B, but not MAO-A, expression 
is upregulated by phorbol esters and that the signal trans-
duction cascade involves c-Jun and Erg-1 [42]. Inspecting 
the 5’-fl anking region of the MAO-A gene we failed to de-
tect consensus sequences for members of the STAT family 
(signal transducer and activator of transcription), suggesting 
that these transcription factor may not be directly involved 
in the expression regulation of the MAO-A gene.
Investigating cytokine-dependent alterations in the gene ex-
pression of human peripheral monocytes using the micro-
array technology, we recently found that the expressions 
of both 15-LOX1 and MAO-A are strongly upregulated in 
IL-4-treated cells [8]. In addition, fi bronectin-1, the Fc-frag-
ment of IgE (CD23A), the CD1C cell surface antigen, and the 
coagulation factor XIII belonged to the most strongly upreg-
ulated gene products [8]. Interestingly, this expression reg-
ulation was isoform-specifi c since neither MAO-B nor other 
LOX isoforms were upregulated [43]. In contrast, we even 
observed signifi cant downregulation of various enzymes of 
the 5-LOX pathway. Mechanistic investigations with transfect-
ed U937 cells suggested that 15-LOX1 may play a role in the 
IL-4-induced signal transduction cascade leading to MAO-A 
expression [43]. Since 15-LOX is involved in the biosynthe-
sis of lipid signal transducers [10], there was the possibility 
that products of the 15-LOX pathway might be involved in 
the signaling cascade. To test this hypothesis we incubated 
wild-type U937 cells with various products of the 15-LOX 
pathway and found that 13S-HpODE and 15S-HpETE, the 
primary products of 15-LOX1-catalyzed oxygenation of lino-
leic acid and arachidonic acid, respectively, induced MAO-
A expression in a dose-dependent manner.
MATERIAL AND METHODS
Materials
The chemicals used were from the following sources: 
Dulbecco’s modifi ed Eagle’s medium (DMEM), RPMI 1640, 
penicillin-streptomycin solution, geneticin (G418 sulphate), 
and L-glutamine from PAA Laboratories GmbH (Colbe, 
Germany); fetal bovine serum (FCS) from Biochrom AG 
(Berlin, Germany); recombinant human IL-4 and IL-13 from 
Strathmann Biotech AG (Hannover, Germany) or Promega 
(Mannheim, Germany); M-MLV reverse transcriptase and 
agarose from Promega (Mannheim, Germany); Pyra exo(-) 
DNA polymerase from Q BIO gene (Illkirch Cedex, France); 
dNTPs from Carl Roth GmbH (Karlsruhe, Germany); DNA 
molecular weight markers (100bp, 1kb) from New England 
Biolabs GmbH (Schwalbach, Germany); arachidonic acid, 
12(S)-hydroxy-(5Z,8Z,10E,14Z)-eicosatetraenoic acid (12S -
-HETE), 15(S)-hydroxy-(5Z,8Z,11Z,13E)-eicosatetraeno-
ic acid (15S-HETE), and soybean LOX-1 (grade 1) from 
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Sigma (Deisenhofen, Germany). PCR primers were custom-
synthesized by BIOTEZ (Berlin, Germany).
Cell culture
U937 (human promyelomonocytic) cells were obtained 
from the German Collection of Microorganisms and Cell 
Cultures (Braunschweig, Germany). Cells were maintained 
in RPMI-1640 or DMEM medium supplemented with 10% 
(v/v) fetal calf serum containing L-glutamine and antibiot-
ics (100 units/ ml penicillin and 100 µg/ml streptomycin) 
at 37°C under 5% CO2.
Reverse transcriptase polymerase chain reaction
Total RNA was isolated using the RNeasy mini kit (Qiagen, 
Hilden, Germany). 3 µg of total RNA was reverse-transcribed 
at 37°C for 170 min in 45 µl 28 mM Tris-HCl buffer, pH = 
8.3, containing 1.7 mM MgCl2, 42 mM KCl, 5.5 mM dithi-
othreitol, 100 µg/ml BSA, 277 µM dNTP’s, 33 ng/µl oligo 
d(T)18 primer, and 200 U reverse transcriptase. To stop the 
reaction, the samples were heated to 94°C for 10 min. The 
RT-sample was diluted 1: 5 and 5 µl were used for ampli-
fi cation. RT-PCR products were separated by 2% agarose 
gel electrophoresis and the DNA bands were stained with 
ethidium bromide. The signal intensity was quantifi ed den-
sitometrically and normalized for expression of glyceralde-
hyde-3-phosphate dehydrogenase mRNA (GAPDH). The 
following primer sequences were used: human GAPDH 
(forward) – 5’-CCA TCA CCA TCT TCC AGG AGC GA-3’, 
human GAPDH (reverse) – 5’-GGA TGA CCT TGC CCA 
CAG CCT TG-3’, rabbit 15-LOX1 (forward) – 5’-ACT GAA 
ATC GGG CTG CAA GGG-3’, rabbit 15-LOX1 (reverse) – 
5’-GGG TGA TGG GGG CTG AAA TAA-3’, human MAO-A 
(forward) - 5’-GCC AAG ATT CAC TTC AGA CCA GAG-3’, 
human MAO-A (reverse) – human MAO-A (reverse) - 5’-TGC 
TCC TCA CAC CAG TTC TTC TC-3’, human MAO-B (for-
ward) – 5’-ACT CGT GTG CCT TTG GGT TCA G-3’, hu-
man MAO-B (reverse) – 5’-TGC TCC TCA CAC CAG TTC 
TTC TC-3’ (same as for MAO-A).
Real-time PCR was carried out on a DNA Engine OpticonÒ 
2 (MJ Research, Inc, Biozym), using the QuantiTect SYBR 
Green PCR Kit from Qiagen, according to the vendor’s pro-
tocol. The primer combinations specifi ed above were used 
and the following PCR protocol was applied: 15 min hot 
start at 95°C, followed by 40 cycles of denaturation (30 s 
at 94°C), annealing (30 s at 60°C), and synthesis (30 s at 
72°C, total volume of 20 µl). For melting curve analysis, the 
temperature was elevated slowly from 60°C to 95°C. Data 
were acquired and analyzed with the Opticon Monitor soft-
ware (version 2).
LOX activity assay
For the determination of 15-LOX1 activity, 5–10×106 cells 
were reconstituted in 0.35 ml of PBS containing 0.16 mM 
arachidonic acid. Following sonication, the lysate was incu-
bated for 20 min at 25°C. The hydroperoxy lipids were re-
duced to the corresponding hydroxy compounds by addi-
tion of 0.1 ml saturated sodium borohydride solution (dry 
methanol). Following addition of 50 µl glacial acetic acid 
and 0.5 ml ice-cold methanol, samples were kept on ice for 
10 min and protein precipitate was removed by centrifu-
gation. Aliquots of the clear supernatant were analyzed by 
HPLC. RP-HPLC was performed with a Shimadzu LC-6A liq-
uid chromatograph connected to a Hewlett Packard diode 
array detector 1040A. Separation of the fatty acid derivatives 
was performed on a Nucleosil C-18 column (Macherey-Nagel, 
Düren, Germany; 250×4 mm, 5-µm particle size) and a guard-
column (30×4 mm, 5-mm particle size, same vendor). The 
solvent system was a mixture of methanol/water/acetic acid 
(80:20:0.2; by vol.) and a fl ow rate of 1 ml/min was used. 
The absorbance at 235 nm was recorded.
Preparation of hydroperoxy fatty acids
13S-HpODE and 15S-HpETE were prepared from the cor-
responding polyenoic fatty acids (linoleic acid and arachi-
donic acid, respectively) using soybean LOX-1. Briefl y, 
1–5 mg of soybean LOX-1 (depending on the specifi c ac-
tivity of the enzyme preparation) were dissolved in 50 ml 
of 0.1 M borate buffer, pH=9.0. Then 1 ml of a methanol-
ic solution of free fatty acid (50 mg/ml) was added drop 
by drop over a time period of about 5 min with permanent 
stirring of the incubation mixture. The sample was allowed 
to incubate for an additional 20 min, the reaction mixture 
was acidifi ed to pH=3, and the lipids were twice extracted 
with 50 ml of diethyl ether. The organic extracts were com-
bined, dried over sodium sulfate, and the solvent was evap-
orated under vacuum. The remaining lipids were reconsti-
tuted in 1 ml of methanol and aliquots were injected for 
RP-HPLC purifi cation using a Shimadzu LC-6A liquid chro-
matograph connected to a Hewlett Packard diode array de-
tector 1040A. Purifi cation of the oxygenated fatty acid was 
performed on a Nucleosil C-18 column (Macherey-Nagel, 
Düren, Germany; 250x4 mm, 5-µm particle size). The sol-
vent system was methanol/water/acetic acid (80:20:0.1; by 
vol) and a fl ow rate of 1 ml/min was used. The absorbance 
at 235 nm was recorded. Since RP-HPLC did not separate 
all hydroperoxy fatty acid isomers with suffi cient effective-
ness, additional SP-HPLC was carried out. For this pur-
pose a Nucleosil 100-7 column (Macherey-Nagel, Düren, 
Germany; 250×4 mm, 5-µm particle size), a solvent system 
of hexane/2-propanol/acetic acid (99:1:0.1, by vol.), and 
a fl ow rate of 1ml/min were used. Chemical identity of the 
prepared hydroperoxy fatty acids was checked by analyt-
ic SP-HPLC, UV-spectroscopy, and gas chromatography/ 
mass spectrometry.
RESULTS
Expression of MAO-A in 15-LOX1-transfected U937 cells: 
It has recently been reported that treatment of human pe-
ripheral monocytes with IL-4 strongly induces upregula-
tion of the expression of MAO-A [43]. A similar upregu-
lation was observed in U937 cells (human monocytic cell 
line) which were transfected with the rabbit 15-LOX1. Thus, 
15-LOX1 appeared to be involved in the signal transduc-
tion cascade leading to the upregulation of MAO-A expres-
sion [43]. To investigate the mechanism of this regulatory 
process in more detail, we fi rst assayed the LOX activity of 
15-LOX1-transfected U937 cells using linoleic acid as ex-
ogenous substrate. For this purpose, 15-LOX1-transfected 
U937 cells and the corresponding mock transfectants were 
incubated with linoleic acid (100 µM fi nal concentration) 
for 15 min at room temperature and the LOX products 
formed were analyzed by RP-HPLC. From Figure 1A it can 
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be seen that the 15-LOX1-transfected cells converted exog-
enous linoleic acid to 13-hydro(pero)xy-9Z,11E-octadecadi-
enoic acid [13-H(p)ODE] and chiral phase HPLC indicated 
a strong preponderance of the S-enantiomer (Figure 1B). 
Such a specifi c product pattern is indicative of an intrinsic 
LOX activity. The chemical structure of the major product 
[13S-H(p)ODE] was confi rmed by co-chromatography with 
authentic standards in SP-HPLC, by UV-spectroscopy, and 
by GC/MS analysis of the hydrogenated derivatives of the 
silylated methyl esters (data not shown). Quantifi cation of 
the product formation indicated that the 15-LOX1-transfect-
ed cells express the enzyme at a moderate level, which is in 
the range of murine peritoneal macrophages [44]. Using 
the corresponding mock transfectants we did not observe 
the formation of specifi c LOX products (Figure 1A, upper 
trace), indicating the absence of 15-LOX1.
To confi rm the absence of 15-LOX1 in wild-type and mock-
transfected U937 cells and to test the expression of MAO-A 
and MAO-B in the 15-LOX1-transfected cells we carried out 
RT-PCR (Figure 2). Initially, semi-quantitative RT-PCR was per-
formed. In these experiments no PCR signals were observed 
in wild-type cells and mock transfectants, but clear PCR bands 
were found in the cells transfected with the rabbit 15-LOX1. 
In contrast, we did not detect MAO-B signals in neither 15-
LOX1-transfected cells nor in the corresponding mock trans-
fectants (Figure 2A). Sequence analysis of the PCR fragments 
confi rmed the identity of the bands. For more quantitative 
data we carried our real-time PCR, and the results are shown 
in Figure 2B. Here again we observed strong upregulation 
of 15-LOX1 and MAO-A expression in the LOX-transfected 
cells, whereas no expression of MAO-B was detected.
IL4-treatment of wild-type U937 cells did also upregulate 
MAO-A expression: Treatment of human peripheral mono-
cytes with IL-4/IL-13 strongly induced MAO-A expression 
[43]. Our transfection studies indicated that expression of 
15-LOX1 in U937 cells also leads to upregulation of MAO-
A, but this effect was independent of IL-4 stimulation. It was 
reported previously that IL-4 treatment of U937 cells does 
not augment 15-LOX1 expression [45,46], and thus it was 
of interest whether or not U937 cells may respond to IL-4 
stimulation with increased expression of MAO-A. Cultured 
macrophages cells express functional IL-4/IL-13 receptors 
and many constituents of the IL-4/IL-13 signaling cascade 
[45,46]. For this study we cultured wild-type U937 cells, 
15-LOX1 transfectants, and the corresponding mock con-
trols for 3 days in the presence of IL-4 and tested the expres-
sion of MAO-A by semi-quantitative RT-PCR. From Figure 3 
it can be seen that wild-type cells and mock transfectants did 
not express MAO-A if the cells were maintained in culture 
for three days in the absence of IL-4. In contrast, when cul-
tured in the presence of IL-4, MAO-A mRNA was detected. 
In the 15-LOX1-transfected cells we observed MAO-A ex-
pression regardless of whether the cells were maintained 
for 3 days in the absence or presence of IL-4.
MAO-A expression in U937 cells is upregulated by 15-LOX 
products: Our transfection studies suggested that the enzy-
Figure 1.  Conversion of linoleic acid by 15-LOX1- transfected and 
mock-transfected U937 cells. Cells were cultured to 
conﬂ uence in culture ﬂ asks as described in Materials and 
Methods. They were harvested by scraping, washed, and 
reconstituted to a ﬁ nal concentration of about 107 cells/ml 
in plain RPMI medium. Then linoleic acid was added as the 
methanolic stock solution top reach a ﬁ nal concentration 
of 100 µM and activity assays were carried out as described 
in the Methods section. Formation of 13S-H(p)ODE was 
quantiﬁ ed by RP-HPLC (panel A) and its enantiomer 
composition was assayed by chiral phase HPLC on a Chiralcel 
OD column (panel B) using hexane/2-propanol/acetic acid 
(100:5:0.1, by vol.) as solvent system and a ﬂ ow rate of 1 
ml/min. This experiment was carried out in triplicate for 
both 15-LOX1-transfected and mock-transfected cells and 
almost identical results were obtained. A representative set 
of chromatograms is shown.
A B
Figure 2.  Expression analysis of 15-LOX1, MAO-A, and MAO-B in 
diﬀ erent types of U937 cells. Wild-type U937 cells, 15-
LOX1-transfectants, and the corresponding mock controls 
were cultured to conﬂ uence, washed, and total RNA was 
extracted. Semi-quantitative RT-PCR (panel A) and real-
time PCR (panel B) were carried out with the crude RNA 
preparations as described in Materials and Methods. These 
experiments were carried out in quadruplicate using 
four diﬀ erent batches of 15-LOX1-transfected and mock-
transfected U937 cells. n.s. not signiﬁ cant, *** p<0.001 
(Students t-test).
A
B
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matic activity of 15-LOX might be involved in the MAO-A 
expression cascade. Since LOX have been implicated in the 
biosynthesis of lipid mediators, we hypothesized that prod-
ucts of the LOX pathway might mimic the upregulation of 
MAO-A expression. To test this hypothesis we incubated wild-
type U937 cells with the stable end products of the 15-LOX 
pathway (the hydroxy fatty acids 15S-HETE and 13S-HODE) 
and checked the expression of MAO-A by semi-quantita-
tive RT-PCR. Unfortunately, we did not observe induction 
of the enzyme (data not shown). Next, the primary lipoxy-
genase products, the hydroperoxy fatty acids (15S-HpETE 
and 13S-HpODE), were tested. Here we detected a dose-
dependent increase in MAO-A mRNA expression when the 
PCR signals were related to b-actin (Figure 4A) or GAPDH 
(data not shown). It should be stressed that the extent of 
MAO-A upregulation was not as dramatic as in IL-4-treated 
monocytes or in 15-LOX1-transfected U937 cells. However, 
it must be kept in mind that in cellular systems, pulses of 
hydroperoxy fatty acids are rapidly reduced to the corre-
sponding hydroxy derivative and thus the effects observed 
in our bolus experiments were expected to be much small-
er than those observed under continuous formation of en-
dogenous hydroperoxy fatty acids.
Intracellular activity of 15-LOX induces an oxidizing envi-
ronment since lipid peroxides are formed endogenously 
[22] and similar effects are introduced when the cells are 
incubated with exogenous hydroperoxy fatty acids. To test 
whether oxidative stress may lead to upregulation of MAO-A 
we incubated U937 cells in the presence of hydrogen per-
oxide and measured the expression of the MAO-A mRNA 
by semi-quantitative RT-PCR. As indicated in Figure 4B, we 
observed an increased MAO-A expression in oxidatively 
stressed cells. In contrast, no major induction of 15-LOX 
or MAO-B was observed (not shown).
DISCUSSION
Recently we reported that the Th2 cytokines IL-4 and IL-13 
strongly induced the expression of MAO-A in human periph-
eral monocytes and in A549 lung carcinoma cells, which nor-
mally do not express the enzyme, in tandem with 15-LOX1 
[43]. A similar upregulation of MAO-A expression was also 
observed in the human promyelomonocytic cell line, U937, 
when transfected with 15-LOX1 [43]. Here we investigated 
the regulatory mechanism of MAO-A expression in more 
detail and identifi ed two alternative pathways which may 
equally contribute to the regulatory effect observed in hu-
man monocytes.
i)  A 15-LOX1-dependent pathway, which is mediated by 
15-LOX1 products (hydroperoxy fatty acids): When wild-
type and mock-transfected U937 cells were incubated with 
primary 15-LOX1 products (15S-HpETE, 13S-HpODE) we 
observed an increase in the steady-state concentration of 
MAO-A mRNA (Figure 4A). These data suggest that for-
mation of endogenous lipid hydroperoxides by the trans-
fected 15-LOX1 is one major reason for upregulation of 
the expression of the MAO-A gene in 15-LOX1-transfected 
U937 cells. This pathway is clearly IL-4 independent, but 
the detailed mechanisms involved remain to be investigat-
ed. It is an open question as to how endogenous peroxides 
can actually activate the expression of the MAO-A gene 
on the molecular level. A search of the putative MAO-A 
promoter did not reveal clear-cut evidence for the exist-
Figure 3.  Expression of MAO-A in diﬀ erent U937 cells cultured in 
the absence or presence of IL-4. Diﬀ erent U937 cells were 
cultured to near conﬂ uence in RPMI medium containing 
10% FCS and antibiotics. Then IL-4 at a ﬁ nal concentration 
of 10 ng/ml was added and the cells were kept in culture 
for additional 3 days. Cells were washed twice, total RNA 
was extracted, and aliquots were used for semi-quantitative 
RT-PCR. The experiment was carried out in triplicate and 
a representative set of data is shown. Densitometric 
quantiﬁ cation of the band intensities and statistic 
evaluation of the quantitative data were not performed.
Figure 4.  Impact of hydroperoxides on MAO-A expression. Wild-
type U937 cells were treated for 24 hours with diﬀ erent 
concentrations of hydroperoxides. After washing, total RNA 
was extracted and the expression of MAO-A mRNA was 
quantiﬁ ed by semi-quantitative RT-PCR using β-actin as 
internal standard. PCR conditions are described in Material 
and Methods. The relative intensities of the RT-PCR signals 
of MAO-A related to β-actin are plotted. Panel A: 13S-
HpODE and 15S-HpETE (primary LOX-products) were used as 
stimuli. Panel B: H2O2 was used as inducer of oxidative stress 
(n=3, p<0.01 between samples and controls).
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ence of redox-sensitive cis-regulatory elements, but work 
is in progress in our laboratory to shed light on this im-
portant question.
ii)  An IL-4-dependent pathway. When wild-type and mock-
transfected U937 cells were cultured for three days in the 
presence of IL-4 we observed the expression of MAO-A 
mRNA (Figure 3). In contrast, no PCR signal was seen 
when the cells were cultured for the same time period 
in the absence of IL-4. U937 cells are unable to respond 
to IL-4 stimulation with upregulation of 15-LOX1 ex-
pression [45,46], and we confi rmed this fi nding in the 
present study (data not shown). DNA methylation stud-
ies indicated that hyper- and hypomethylation of CpG 
islands in the 15-LOX1 promoter region is intimately 
associated with transcriptional repression or activation 
of the 15-LOX1 gene, respectively. [46]. The 15-LOX1 
promoter was exclusively methylated in cells incapable 
of expressing 15-LOX1 in response to IL-4 stimulation 
(including U937 cells). In contrast, cells containing an 
unmethylated promoter, such as peripheral monocytes 
or A549 cells, respond to IL-4 application with expression 
of 15-LOX1. Our fi nding that IL-4-treated U937 cells ex-
pressed MAO-A at signifi cant levels although 15-LOX1 
was absent suggested the existence of an IL-4-depend-
ent, but 15-LOX1-independent, induction mechanism. 
In the light of these fi ndings it may be concluded that 
in human peripheral monocytes, which respond to IL-4 
stimulation with an increase in 15-LOX expression, up-
regulation of MAO-A may follow a dual mechanism, 
with a 15-LOX1-dependent and a15-LOX1-independ-
ent share.
The biological importance of IL-4-induced upregulation of 
15-LOX1 and MAO-A expression for monocyte physiology 
remains to be investigated. We recently profi led the gene 
expression pattern of IL-4-treated human peripheral mono-
cytes using the microarray technology and found upregula-
tion of a variety of classical anti-infl ammatory gene products 
and concomitant down-regulation of pro-infl ammatory pro-
teins [8]. Thus, IL-4 may switch naive monocytes into cells 
with dominant anti-infl ammatory phenotype, which play a 
major role in infl ammatory resolution. It has been suggested 
before that 15-LOXs may be involved in the biosynthesis of 
lipoxins [47,48], which constitute potent anti-infl ammatory 
mediators which are synthesized during the resolution of 
acute infl ammation. The expression profi le of various LOX 
isoforms during the time course of infl ammation indicated 
that polymorphonuclear leukocytes turn on the expression 
of functional 15-LOX1 when developing from pro-infl am-
matory to resolving cells [49]. A similar phenotype switch 
may be induced by IL-4 in human monocytes.
The role of MAO-A in a putative anti-infl ammatory response 
remains to be investigated. Biogenic amines, such as hista-
mine and serotonin, are well-known infl ammatory media-
tors [50–52]. They have also been implicated in neuroim-
mune interactions and modulation of blood-brain barrier 
permeability [53]. Since MAO-A preferentially oxidizes se-
rotonin, the enzyme might be involved in the removal of 
this pro-infl ammatory mediator from the site of infl amma-
tion. In this respect, IL-4/IL-13-induced upregulation of 
MAO-A might contribute to switching monocytes from a 
pro- to an anti-infl ammatory phenotype.
CONCLUSIONS
Resting monocytic cells (peripheral human monocytes, 
U937 cells) express neither MAO-A nor MAO-B. However, 
transfection of U937 cells with 15-LOX1, incubation with 
the 15-LOX1 products 13S-HpODE and 15S-HpETE, or cul-
turing the cells in the presence of the Th2 cytokine IL-4 
strongly induced MAO-A expression. In contrast, MAO-B 
expression remained unaffected. These data suggest that 
the previously reported IL-4-induced upregulation of MAO-
A expression in human peripheral monocytes may proceed 
via 15-LOX1-dependent and 15-LOX1-independent path-
ways. Upregulation of MAO-A expression may contribute in 
switching naive monocytes into a resolving phenotype.
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